AVROBIO Inc at JMP Securities Life Sciences Virtual Conference Transcript
Great. Good morning, everyone, and welcome to the second day of JMP Securities Life Science Conference. My name is Ren Benjamin. I am a senior biotechnology analyst here. And it's my distinct pleasure to introduce AVROBIO, a company focused on ex vivo lentiviral-based gene therapy, with an initial focus on lysosomal disorders, where you may have a standard of care, but -- such as enzyme replacement therapy, but it doesn't halt the disease progression and a lot of times, doesn't adequately address a lot of the symptoms. So here to tell us more about the Company is CEO, Geoff MacKay. Geoff, take it away.
Thanks, Reni, and thank you, everybody, for tuning in. I look forward to highlighting the recent progress at AVROBIO. Quickly before we begin, the presentation will contain forward-looking statements based on our current expectations and beliefs. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |